Contrive Datum Insights has published "Patient Registry Software Market Size, Share & Industry Analysis, By Registry type (Cardiovascular Registry, Diabetes Registry, Cancer Registry, Rare Disease Registry, Other Disease Registries, Health Service Registry, Medical Device Registry, Drug Registry), Software type (Standalone, Integrated), Application (Government Organizations and Third-party Administrators (TPAs), Hospitals and Medical Practices, Private Payers, Pharmaceutical, Biotechnology and Medical Device Companies, Research Center), Functionality (Population Health Management, Health Information Exchange, Patient Care Management, Medical Research and Clinical Studies, Others), Deployment mode (Cloud-based, On-premise), and Regional Forecast, 2026-2034". The study sizes the global patient registry software market at USD 2200 million in 2025 and projects growth from USD 2453 million in 2026 to USD 5860 million by 2034, a compound annual growth rate of 11.5% across the forecast period.
Patient registry software is a category of health information technology used to systematically collect, store and analyze structured patient data tied to a specific disease, procedure, medical product or care pathway over time. It is delivered as standalone applications or as modules integrated into broader electronic health record and population-health platforms, hosted either on a vendor's cloud infrastructure or within a customer's own data center. Buyers include hospital systems, government health agencies, private payers, pharmaceutical and medical device companies, and academic or clinical research centers that need longitudinal patient data for care management, quality reporting or post-market surveillance.
Regulatory mandates for real-world evidence and post-market surveillance reporting
Regulatory mandates for real-world evidence and post-market surveillance reporting is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.5% a year, the registry type lines exposed to it move fastest: Rare Disease Registry compounds at 14.78%, taking its share of revenue from 10% to 13% and its value from USD 220 million to USD 762 million.
The study also runs a bull case: registry mandates expand faster than expected across major health agencies, and hospital systems compress their cloud-migration timelines, pulling forward licensing upgrades and seat growth. That path ends 2034 at USD 6739 million, above the USD 5860 million base case.
On the downside, public health agencies delay new registry mandates under budget pressure, and hospital systems extend the replacement cycle for on-premise systems, slowing both new deployments and the cloud upgrade rate, which would hold 2034 revenue to USD 4981 million. Cardiovascular Registry, which carries 20% of 2025 revenue, already grows at only 10.21% against the market's 11.5%, so the largest part of the base is also its slowest.
The Competitive Split Runs by Registry type
The registry type axis, not the regional one, is what divides the field. Cardiovascular Registry is the volume position, 20% of 2025 revenue at USD 440 million, holding 18% through 2034, and it is defended by scale. Rare Disease Registry is the growth position at 14.78%, and it is open. Strength in one does not carry into the other.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Software type | Integrated | 65% · USD 1430 million | — |
| Application | Hospitals and Medical Practices | 30% · USD 660 million | Research Center 14.83% |
| Functionality | Population Health Management | 28% · USD 616 million | Medical Research and Clinical Studies 14.08% |
| Deployment mode | Cloud-based | 58% · USD 1276 million | — |
- North America was the largest region in 2025, holding 44% of global revenue at USD 968 million and reaching USD 2344 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 18% in 2025 to 23% in 2034, with revenue growing from USD 396 million to USD 1348 million.
- Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 5% by 2034.
- By registry type, the largest line in 2025 was Cardiovascular Registry, at 20% of revenue and USD 440 million.
- The fastest registry type line is Rare Disease Registry, forecast to compound at 14.78% through the period.
- The United States is the largest single country market at USD 823 million in 2025, 37.41% of global revenue.
Coverage runs to five axes, by registry type, and by software type, application, functionality and deployment mode, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 4981 million and USD 6739 million by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.